Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Genomic Health Inc (GHDX)

Genomic Health Inc (GHDX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Genomic Health I Up 26.3% Since SmarTrend Uptrend Call (GHDX)

SmarTrend identified an Uptrend for Genomic Health I (NASDAQ:GHDX) on July 1st, 2019 at $58.61. In approximately 2 month, Genomic Health I has returned 26.35% as of today's recent price of $74.06.

GHDX : 74.48 (-0.21%)
CDOR, GHDX, TYPE, and UBNK SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Acquisitions

Rigrodsky & Long, P.A. announces that it is investigating:

GHDX : 74.48 (-0.21%)
CDOR : 11.00 (+0.09%)
TYPE : 19.89 (+0.20%)
UBNK : 12.74 (+1.27%)
Shareholder Investigation Alert: Halper Sadeh LLP is Investigating Whether the Sale of These Companies is Fair to Shareholders - UBNK, TYPE, GHDX, NCI

Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

GHDX : 74.48 (-0.21%)
NCI : 27.88 (+0.04%)
UBNK : 12.74 (+1.27%)
TYPE : 19.89 (+0.20%)
Amgen (AMGN) Soars to 52-Week High, Time to Cash Out?

Amgen (AMGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

GHDX : 74.48 (-0.21%)
AMGN : 204.17 (+0.07%)
BIIB : 235.77 (+1.77%)
ALXN : 113.08 (+2.01%)
New Publication Shows Different Result of Risk Classification between GenesWell BCT and Oncotype DX in Breast Cancer Patients 50 Years Old or Younger.

Gencurix, Inc., a company dedicated in development and market of innovative molecular diagnostics, announced the publication of a new study on Frontiers in Oncology comparing GenesWell(TM) BCT, a prognostic...

GHDX : 74.48 (-0.21%)
URGENT: Monteverde & Associates PC is Investigating the Following Transaction

Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating:

GHDX : 74.48 (-0.21%)
EXAS : 119.32 (-0.42%)
NCI : 27.88 (+0.04%)
CVRS : 4.26 (-0.23%)
WAIR : 10.99 (+0.27%)
GCI : 9.95 (+1.02%)
VSI : 6.43 (unch)
CBM : 59.24 (-1.09%)
Shares of GHDX Up 24.8% Since Uptrend Call on Shares

SmarTrend identified an Uptrend for Genomic Health I (NASDAQ:GHDX) on July 1st, 2019 at $58.62. In approximately 1 month, Genomic Health I has returned 24.81% as of today's recent price of $73.16.

GHDX : 74.48 (-0.21%)
Robbins Arroyo LLP: Acquisition of Genomic Health, Inc. (GHDX) by Exact Sciences Corp. (EXAS) May Not Be in Shareholders' Best Interests

Shareholder rights attorneys at Robbins Arroyo LLP are investigating the proposed acquisition of Genomic Health, Inc. (NASDAQ: GHDX) by Exact Sciences Corp. (NASDAQ: EXAS). On July 29, 2019, the two companies...

GHDX : 74.48 (-0.21%)
EXAS : 119.32 (-0.42%)
Genomic Health, Inc. (GHDX) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Genomic Health, Inc. (GHDX).

GHDX : 74.48 (-0.21%)
GENOMIC HEALTH INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Genomic Health, Inc. - GHDX

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Genomic Health, Inc. (NasdaqGS: GHDX) to Exact...

GHDX : 74.48 (-0.21%)
EXAS : 119.32 (-0.42%)
Genomic Health (GHDX) to Join Exact Sciences, Posts Q2 Results

The merger of Genomic Health (GHDX) with Exact Sciences will combine two of the strongest brands in cancer diagnostics, Cologuard and OncotypeDX, providing platform for growth.

SYK : 217.03 (+0.01%)
GHDX : 74.48 (-0.21%)
EXAC : 49.25 (unch)
BAX : 87.59 (+0.71%)
ISRG : 493.06 (-0.48%)
Rigrodsky & Long, P.A. Reminds Investors of Investigations of the Following Acquisitions

Rigrodsky & Long, P.A. announces that it is investigating:

GHDX : 74.48 (-0.21%)
HWC : 36.62 (+1.89%)
MSL : 10.77 (+1.51%)
ORIT : 17.07 (+1.07%)
TYPE : 19.89 (+0.20%)
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of the Following Acquisitions

Rigrodsky & Long, P.A. announces that it is investigating:

LTXB : 40.49 (+0.85%)
GHDX : 74.48 (-0.21%)
CZR : 11.56 (+0.09%)
TYPE : 19.89 (+0.20%)
Shareholder Investigation Alert: Halper Sadeh LLP Reminds Investors That it is Investigating Whether the Sale of These Companies is Fair to Shareholders - TSS, TYPE, GHDX

Halper Sadeh LLP, a global investor rights law firm, reminds investors that it is investigating the following companies:

GHDX : 74.48 (-0.21%)
TSS : 128.16 (+0.64%)
TYPE : 19.89 (+0.20%)
Genomic Health I Has Returned 25.9% Since SmarTrend Recommendation (GHDX)

SmarTrend identified an Uptrend for Genomic Health I (NASDAQ:GHDX) on July 1st, 2019 at $58.62. In approximately 4 weeks, Genomic Health I has returned 25.86% as of today's recent price of $73.77.

GHDX : 74.48 (-0.21%)
Alkermes Plc has the Best Relative Performance in the Biotechnology Industry (ALKS , GHDX , NBIX , ACAD , RGEN )

Here are the top 5 stocks in the Biotechnology industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were outperforming....

GHDX : 74.48 (-0.21%)
NBIX : 98.07 (+0.85%)
ALKS : 21.97 (+1.48%)
SHAREHOLDER ALERT: WeissLaw LLP Investigates Genomic Health, Inc.

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Genomic Health, Inc. ("Genomic Health" or the "Company") (NASDAQ: GHDX) in connection...

GHDX : 74.48 (-0.21%)
EXAS : 119.32 (-0.42%)
Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Genomic Health, Inc. (NASDAQ: GHDX) on Behalf of Genomic Shareholders and Encourages Genomic Investors to Contact the Firm

Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of Genomic Health, Inc. (NASDAQ: GHDX) on behalf of Genomic shareholders concerning the proposed merger with...

GHDX : 74.48 (-0.21%)
EXAS : 119.32 (-0.42%)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Genomic Health, Inc. to Exact Sciences Corp. is Fair to Shareholders

The following statement is being issued by Levi & Korsinsky, LLP:

GHDX : 74.48 (-0.21%)
EXAS : 119.32 (-0.42%)
SmarTrend Watching for Potential Pullback in Shares of Genomic Health I After 3.54% Gain

Genomic Health I (NASDAQ:GHDX) traded in a range yesterday that spanned from a low of $65.81 to a high of $71.24. Yesterday, the shares gained 3.5%, which took the trading range above the 3-day high...

GHDX : 74.48 (-0.21%)

Van Meerten Stock Picks

AMD - Volume Leader
The Volume Leader today is the semiconductor company Advanced Micro Devices (AMD).
AMD +0.82
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar